Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health treatment, announced that CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston. The presentation is scheduled for Monday, Nov. 9, 2026, at 3 p.m. ET. The fireside chat will be webcast live, with registration available through the conference webcast platform, and a replay will be available on the Events & Presentations page of the company’s investor relations website.
The conference appearance is significant because it offers Helus Pharma a high-visibility platform to engage with investors, analysts, and industry peers at a time when mental health treatments remain a large unmet need. The company’s proprietary NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, and they are intended to address depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through durable improvements in mental health.
Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, the company has an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com.
The fireside chat comes as Helus Pharma continues to advance its clinical programs and seek to differentiate itself in the competitive neuropsychiatry space. Participation at the Guggenheim conference may enhance the company’s visibility among institutional investors and potential partners, especially given the Breakthrough Therapy Designation for HLP003, which could expedite development and review. The live webcast and replay also allow a broader audience to access management’s commentary on strategy and progress.
The announcement was disseminated on behalf of Helus Pharma and may include paid advertising. The full press release is available at https://ibn.fm/LrRvm. The dissemination was handled by InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN, which provides editorial syndication to 5,000+ outlets and social media distribution to millions of followers. Terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
